Efficacy, compliance and toxicity factors are affecting the rate of normalization of body Iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy

Hemoglobin

Volumn 35, Issue 3, 2011, Pages 186-198

  Kolnagou, Annita ^a   Kleanthous, Marios ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Deferasirox (DFRA); Deferiprone (L1); Deferoxamine (DFO); Iron overload; Normal iron stores; Thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; CREATININE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LIVER ENZYME; UREA;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA MAJOR; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HUMAN; IRON STORAGE; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT MONITORING; RELAXATION TIME; THALASSEMIA; UREA BLOOD LEVEL;

BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PYRIDONES;

EID: 79957497558     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.576153     Document Type: Conference Paper

References (30)

1. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30(2): 239-249 (Pubitemid 43977326)
2. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2): 41-47 (Pubitemid 351264511)
3. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5): 430-438
4. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3): 466-475
5. Kolnagou A, Kontoghiorghes GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol. 2010;150(4): 489-490
6. Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1-2): 17-28 (Pubitemid 351264514)
7. Kolnagou A, Kontoghiorghes GJ. Maintenance of normal range body iron store levels for up to 45 years in thalassemia major patients using deferiprone monotherapy. Hemoglobin. 2010;34(3): 204-209
8. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23): 2171-2179 (Pubitemid 33139463)
9. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion dependent thalassemia and sickle cell disease. Blood. 2004;103(5): 1934-1936 (Pubitemid 38268994)
10. Tanner MA, Galanello R, Dessi C et al. A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14): 1876-1884 (Pubitemid 46598901)
11. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll, and their combinations. Curr Med Chem. 2005;12(23): 2663-2681 (Pubitemid 41601566)
12. Sheppard L, Kontoghiorghes GJ. Competition between L1, desferrioxamine and other chelators for iron and the effect of other metal ions on iron binding. Arzn Forsch/Drug Res. 1993;43(6): 659-663
13. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23): 2695-2709 (Pubitemid 41601568)
14. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1): 401-408 (Pubitemid 47026862)
15. Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy. J Am Soc Nephrol. 2007;18: 329A.
16. Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol. 2007;18: 57-58A.
17. Forni GL, Balocco M, Cremonesi L, et al. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008;23(6): 904-907
18. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. (Elite Ed) 2009;1: 161-178
19. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2): 20 1-206
20. Aessopos A, Kati M, Farmaki D, et al. Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol. 2007;86(3): 212-215 (Pubitemid 350085808)
21. Kolnagou A, Yazman D, Economides Ch, Eracleous E, Kontoghiorghes GJ. Uses and limitationsof serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin. 2009;33(5): 312-322
22. Kolnagou A, Eracleous E, Economides Ch, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting excess cardiac iron loading and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin. 2006;30(2): 219-227 (Pubitemid 43977324)
23. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653): 27-30 (Pubitemid 19158169)
24. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998;850: 227-231 (Pubitemid 28369763)
25. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88(12): 1423-25 (Pubitemid 38029728)
26. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9(4): 633-641
27. Kontoghiorghes GJ.A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5): 332-338
28. Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin. 2006;30(2): 183-200
29. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4): 537-543
30. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2010;96(1): 41-47